Control of bleeding in cancer.
Department of Hematology-Oncology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile. jpereira@med.puc.cl
Jaime
J
Pereira
D000925:Anticoagulants / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001779:Blood Coagulation Factors / Q000627:therapeutic use; D001803:Blood Transfusion; D004621:Embolization, Therapeutic; D015942:Factor VIIa / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006470:Hemorrhage / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control / Q000532:radiotherapy / Q000628:therapy*; D006489:Hemostatic Techniques; D006490:Hemostatics / Q000627:therapeutic use; D006801:Humans; D052016:Mucositis / Q000139:chemically induced / Q000150:complications; D009361:Neoplasm Invasiveness; D009369:Neoplasms / Q000097:blood / Q000150:complications*; D010265:Paraproteinemias / Q000097:blood / Q000150:complications; D011994:Recombinant Proteins / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000209:etiology / Q000628:therapy; D013923:Thromboembolism / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control
D000925:Anticoagulants; D000970:Antineoplastic Agents; D001779:Blood Coagulation Factors; D005343:Fibrinolytic Agents; D006490:Hemostatics; D011994:Recombinant Proteins; C025667:prothrombin complex concentrates; C103587:recombinant FVIIa; D015942:Factor VIIa